Read twice and referred to the Committee on Finance.
The bill amends Medicare Part D (Social Security Act title XVIII) to treat plasma-derived products specially under the Part D manufacturer discount program. It defines “plasma-derived product,” creates a new “specified plasma-derived product percent,” and sets phased percentages of the negotiated price to be used as the “discounted price” for such products from 2026 through 2032 and beyond.
Liberal emphasizes access protection; conservatives emphasize federal intervention concerns.
Narrow, industry-targeted change may attract coalition support but could face opposition over cost and precedent.
The bill amends Medicare Part D (Social Security Act title XVIII) to treat plasma-derived products specially under the Part D manufacturer discount program.
It defines “plasma-derived product,” creates a new “specified plasma-derived product percent,” and sets phased percentages of the negotiated price to be used as the “discounted price” for such products from 2026 through 2032 and beyond.
The phase‑in differs depending on whether a beneficiary has reached the annual out‑of‑pocket threshold; certain drugs for low‑income subsidy beneficiaries and specified small manufacturers are excluded.
Technically narrow and administrable, but fiscal effects and industry tilt reduce standalone viability absent wider deal or offsets.
How solid the drafting looks.
Liberal emphasizes access protection; conservatives emphasize federal intervention concerns.
These are examples from the analysis, not a ranked list of the most-affected groups.
Liberal emphasizes access protection; conservatives emphasize federal intervention concerns.
Likely viewed as a targeted adjustment to reduce abrupt financial or supply disruptions for essential plasma-derived medicines.
Supporters would see the phase-in as protecting patient access to lifesaving biological therapies while allowing time for market adjustment.
Views the measure as a pragmatic, technical phase‑in intended to avoid market disruption.
Would seek fiscal estimates and implementation detail to judge tradeoffs between access protection and potential cost‑shifting.
Likely skeptical or opposed because it changes federal rules governing manufacturer financial obligations and interferes in drug pricing mechanics.
May view it as regulatory expansion that could produce unintended fiscal consequences.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Technically narrow and administrable, but fiscal effects and industry tilt reduce standalone viability absent wider deal or offsets.
The bill has not accumulated any surfaced votes yet.
Liberal emphasizes access protection; conservatives emphasize federal intervention concerns.
Technically narrow and administrable, but fiscal effects and industry tilt reduce standalone viability absent wider deal or offsets.
Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for PLASMA Act.
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.